2251 Stock Overview
Provides artificial intelligence (AI) empowered retina-based early detection, diagnosis, and health risk assessment solutions for medical institutions, consumer healthcare environments, and eye health management settings in Mainland China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 2251 from our risk checks.
Beijing Airdoc Technology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$11.46 |
| 52 Week High | HK$18.38 |
| 52 Week Low | HK$9.60 |
| Beta | 0.87 |
| 11 Month Change | 2.50% |
| 3 Month Change | -0.35% |
| 1 Year Change | -4.02% |
| 33 Year Change | -82.50% |
| 5 Year Change | n/a |
| Change since IPO | -83.15% |
Recent News & Updates
Recent updates
These Analysts Just Made A Massive Downgrade To Their Beijing Airdoc Technology Co., Ltd. (HKG:2251) EPS Forecasts
Sep 03
Sentiment Still Eluding Beijing Airdoc Technology Co., Ltd. (HKG:2251)
Aug 08Investors Appear Satisfied With Beijing Airdoc Technology Co., Ltd.'s (HKG:2251) Prospects As Shares Rocket 33%
Apr 03Are Investors Undervaluing Beijing Airdoc Technology Co., Ltd. (HKG:2251) By 49%?
Mar 02We Think Beijing Airdoc Technology (HKG:2251) Can Afford To Drive Business Growth
Feb 02The Beijing Airdoc Technology Co., Ltd. (HKG:2251) Analysts Have Been Trimming Their Sales Forecasts
Sep 19Calculating The Intrinsic Value Of Beijing Airdoc Technology Co., Ltd. (HKG:2251)
Sep 01We're Not Very Worried About Beijing Airdoc Technology's (HKG:2251) Cash Burn Rate
Jun 09Shareholder Returns
| 2251 | HK Healthcare Services | HK Market | |
|---|---|---|---|
| 7D | 0.5% | 3.5% | 0.4% |
| 1Y | -4.0% | -11.2% | 12.0% |
Return vs Industry: 2251 exceeded the Hong Kong Healthcare Services industry which returned -11.2% over the past year.
Return vs Market: 2251 underperformed the Hong Kong Market which returned 12% over the past year.
Price Volatility
| 2251 volatility | |
|---|---|
| 2251 Average Weekly Movement | 7.7% |
| Healthcare Services Industry Average Movement | 7.8% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 18.9% |
| 10% least volatile stocks in HK Market | 4.3% |
Stable Share Price: 2251 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2251's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 254 | Ray Zhang | www.airdoc.com |
Beijing Airdoc Technology Co., Ltd. provides artificial intelligence (AI) empowered retina-based early detection, diagnosis, and health risk assessment solutions for medical institutions, consumer healthcare environments, and eye health management settings in Mainland China and internationally. It offers Airdoc-AIFUNDUS (1.0), an AI-empowered retina-based auxiliary diagnosis product; Airdoc-AIFUNDUS (2.0) for the auxiliary diagnosis of hypertensive retinopathy, retinal vein occlusion, and age-related macular degeneration; Airdoc-AIFUNDUS (3.0) for the auxiliary diagnosis of pathological myopia and retinal detachment; and glaucoma, cataracts, ICVD and ASCVD, gestational diabetic retinopathy, gestational hypertensive retinopathy, papilledema intracranial hypertension retinopathy, and anemia SaMDs. The company also provides health risk assessment solutions to detect risk indicators, such as retinal abnormalities, retinal vascular diseases, vitreous abnormalities, retinal tumors, optic nerve pathologies, macular diseases, congenital anomalies of the retina, cardiovascular diseases, and anemia to various healthcare providers, including health checkup centers, insurance companies, optometry centers, and pharmacies.
Beijing Airdoc Technology Co., Ltd. Fundamentals Summary
| 2251 fundamental statistics | |
|---|---|
| Market cap | HK$1.17b |
| Earnings (TTM) | -HK$189.22m |
| Revenue (TTM) | HK$231.25m |
5.1x
P/S Ratio-6.2x
P/E RatioIs 2251 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2251 income statement (TTM) | |
|---|---|
| Revenue | CN¥215.17m |
| Cost of Revenue | CN¥87.65m |
| Gross Profit | CN¥127.53m |
| Other Expenses | CN¥303.59m |
| Earnings | -CN¥176.06m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.72 |
| Gross Margin | 59.27% |
| Net Profit Margin | -81.83% |
| Debt/Equity Ratio | 0% |
How did 2251 perform over the long term?
See historical performance and comparison